Targeted Delivery of Liposomal Ribociclib to SLC7A5 Transporters in Breast Cancer Cells

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2023 Dec 21

PMID 38127209

Authors

Mahtab Afsharzadeh

Jaleh Varshosaz

Mina Mirian

Farshid Hasanzadeh

Affiliations

Soon will be listed here.

Abstract

This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, Asp, Glu amino acids to liposomes as targeting moieties. The liposomes were optimized for their formulations. Cell analysis on two cell lines of MCF-7 and NIH-3T3 were done including; cell viability test by MTT assay, cellular uptake, and cell cycle arrest by flow cytometry. The optimal liposomes showed the particle size of 123.6 ± 1.3 nm, drug loading efficiency and release efficiency of 83.87% ± 1.33% and 60.55% ± 0.46%, respectively. The RB loaded liposomes showed no hemolysis activity. Targeted liposomes increased cytotoxicity on MCF-7 cells more significantly than NIH-3T3 cells. Cell flow cytometry indicated that targeted liposomes uptake was superior to plain (non-targted) liposomes and free drug. Free drug and RB-loaded liposomes interrupted cell cycle in G1. However, amino acid-targeted liposomes arrested cells more than the free drug at this stage. Targeted liposomes reduced cell cycle with more interruption in the G2/M phase compared to the negative control.

References

Al-Mahmood S, Sapiezynski J, Garbuzenko O, Minko T . Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res. 2018; 8(5):1483-1507. PMC: 6133085. DOI: 10.1007/s13346-018-0551-3. View

Finn R, Aleshin A, Slamon D . Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016; 18(1):17. PMC: 4746893. DOI: 10.1186/s13058-015-0661-5. View

Slamon D, Neven P, Chia S, Fasching P, De Laurentiis M, Im S . Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2019; 382(6):514-524. DOI: 10.1056/NEJMoa1911149. View

Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q . FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2018; 24(13):2999-3004. DOI: 10.1158/1078-0432.CCR-17-2369. View

Liu D, Yang F, Xiong F, Gu N . The Smart Drug Delivery System and Its Clinical Potential. Theranostics. 2016; 6(9):1306-23. PMC: 4924501. DOI: 10.7150/thno.14858. View

Hurler J, Zakelj S, Mravljak J, Pajk S, Kristl A, Schubert R . The effect of lipid composition and liposome size on the release properties of liposomes-in-hydrogel. Int J Pharm. 2013; 456(1):49-57. DOI: 10.1016/j.ijpharm.2013.08.033. View

Guimaraes D, Cavaco-Paulo A, Nogueira E . Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021; 601:120571. DOI: 10.1016/j.ijpharm.2021.120571. View

Gynther M, Jalkanen A, Lehtonen M, Forsberg M, Laine K, Ropponen J . Brain uptake of ketoprofen-lysine prodrug in rats. Int J Pharm. 2010; 399(1-2):121-8. DOI: 10.1016/j.ijpharm.2010.08.019. View

Wu W, Dong Y, Gao J, Gong M, Zhang X, Kong W . Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors. Cancer Sci. 2015; 106(6):747-756. PMC: 4471785. DOI: 10.1111/cas.12672. View

10.

Metselaar J, Bruin P, de Boer L, de Vringer T, Snel C, Oussoren C . A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem. 2003; 14(6):1156-64. DOI: 10.1021/bc0340363. View

11.

Brandl M . Liposomes as drug carriers: a technological approach. Biotechnol Annu Rev. 2001; 7:59-85. DOI: 10.1016/s1387-2656(01)07033-8. View

12.

Hua S, Wu S . The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol. 2013; 4:143. PMC: 3836271. DOI: 10.3389/fphar.2013.00143. View

13.

Accardo A, Morelli G . Review peptide-targeted liposomes for selective drug delivery: Advantages and problematic issues. Biopolymers. 2015; 104(5):462-79. DOI: 10.1002/bip.22678. View

14.

Hong S, Kim S, Lim S . Effects of triglycerides on the hydrophobic drug loading capacity of saturated phosphatidylcholine-based liposomes. Int J Pharm. 2015; 483(1-2):142-50. DOI: 10.1016/j.ijpharm.2015.02.013. View

15.

Kaddah S, Khreich N, Kaddah F, Charcosset C, Greige-Gerges H . Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule. Food Chem Toxicol. 2018; 113:40-48. DOI: 10.1016/j.fct.2018.01.017. View

16.

Arnida , Janat-Amsbury M, Ray A, Peterson C, Ghandehari H . Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm. 2010; 77(3):417-23. PMC: 3379889. DOI: 10.1016/j.ejpb.2010.11.010. View

17.

Sartaj A, Annu , Biswas L, Verma A, Sahoo P, Baboota S . Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating Specification, and Scrutinization. Biomed Res Int. 2022; 2022:6009309. PMC: 8831049. DOI: 10.1155/2022/6009309. View

18.

Nakanishi T, Tamai I . Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. J Pharm Sci. 2011; 100(9):3731-50. DOI: 10.1002/jps.22576. View

19.

Salatin S, Dizaj S, Khosroushahi A . Effect of the surface modification, size, and shape on cellular uptake of nanoparticles. Cell Biol Int. 2015; 39(8):881-90. DOI: 10.1002/cbin.10459. View

20.

Dickson M . Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res. 2014; 20(13):3379-83. DOI: 10.1158/1078-0432.CCR-13-1551. View